Angela Casbard

2020

• Jones, R.et al. 2020. A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International (10.1111/bju.15096)
• Jones, R. H.et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21(3), pp. 345-347. (10.1016/S1470-2045(19)30817-4)

2018

• Lester, J. F.et al. 2018. A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. OncoImmunology 7(12), article number: e1457597. (10.1080/2162402X.2018.1457597)

2017

• Gillespie, D.et al. 2017. The use of randomisation-based efficacy estimators in non-inferiority trials. Trials 18(1), article number: 117. (10.1186/s13063-017-1837-3)

2016

• Harrop, E.et al. 2016. Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy). Trials 17, article number: 35. (10.1186/s13063-016-1173-z)
• Jones, R. J.et al. 2016. TOUCAN: A randomised phase II trial of carboplatin and gemcitabine plus /- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin [Abstract]. American Journal of Clinical Oncology 34(S25), article number: 448.

2015

• Gillespie, D.et al. 2015. The use of randomisation-based efficacy estimators in non-inferiority trials [Poster Presentation]. Trials 16(Suppl), pp. P129. (10.1186/1745-6215-16-S2-P129)
• Noble, S. I.et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
• Geldart, T.et al. 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67(4), pp. 599-602. (10.1016/j.eururo.2014.11.003)

2014

• Noble, S.et al. 2014. ALICAT: Anticoagulation length in cancer associated thrombosis - a mixed-methods feasibility study. Thrombosis Research 133(Supp 2), pp. S220-S220. (10.1016/S0049-3848(14)50032-1)
• Barrett-Lee, P.et al. 2014. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncology 15(1), pp. 114-122. (10.1016/S1470-2045(13)70539-4)
• Smith, J. D.et al. 2014. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study. Trials 15(1), article number: 122. (10.1186/1745-6215-15-122)
• Noble, S. I. R.et al. 2014. Anticoagulation length in cancer associated thrombosis: a mixed-methods feasibility study. Presented at: International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, 9-11 May 2014.

2009

• Nixon, L. S.et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21(3), pp. 255-255. (10.1016/j.clon.2009.01.001,)
• Morgan, M. A.et al. 2009. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. British Journal of Surgery 96(11), pp. 1300-1307. (10.1002/bjs.6705)
• Llewelyn, C. A.et al. 2009. The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies. Transfusion Medicine 19(2), pp. 89-98. (10.1111/j.1365-3148.2009.00911.x)
• Wells, A. W.et al. 2009. The EASTR Study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. Transfusion Medicine 19(6), pp. 315-328. (10.1111/j.1365-3148.2009.00933.x)
• Cooke, D.et al. 2009. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA1cin insulin-treated diabetes (MITRE Study). Diabetic Medicine 26(5), pp. 540-547. (10.1111/j.1464-5491.2009.02723.x)

2007

• Williamson, L. M.et al. 2007. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 47(8), pp. 1455-1467. (10.1111/j.1537-2995.2007.01281.x)
• Ghevaert, C.et al. 2007. HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia. Transfusion 47(7), pp. 1296-1305. (10.1111/j.1537-2995.2007.01273.x)

2006

• Stanworth, S. J.et al. 2006. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding. Vox Sanguinis 91(1), pp. 63-69. (10.1111/j.1423-0410.2006.00785.x)
• Williamson, M.et al. 2006. Haemovigilance reports of post-transfusion purpura and transfusion-associated graft-versus-host disease before and after implementation of universal leucocyte depletion in the UK. Vox Sanguinis 91(Supp 3), pp. 15-15. (10.1111/j.0042-9007.2006.vox_v91_is3_mondaysessions.x)
• Davies, A.et al. 2006. End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses. Transfusion 46(3), pp. 352-364. (10.1111/j.1537-2995.2006.00729.x)
• Grover, M.et al. 2006. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sanguinis 90(2), pp. 105-112. (10.1111/j.1423-0410.2006.00730.x)

2005

• Buck, J.et al. 2005. Preoperative transfusion in sickle cell disease: a survey of practice in England. European Journal of Haematology 75(1), pp. 14-21. (10.1111/j.1600-0609.2005.00412.x)
• Segal, H. C.et al. 2005. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. British Journal of Haematology 128(4), pp. 520-525. (10.1111/j.1365-2141.2004.05352.x)

2004

• Allain, J.et al. 2004. Sociology and behaviour of West African blood donors: the impact of religion on human immunodeficiency virus infection. Vox Sanguinis 87(4), pp. 233-240. (10.1111/j.1423-0410.2004.00578.x)
• McPherson, K.et al. 2004. Severe complications of hysterectomy: the VALUE study. BJOG - an International Journal of Obstetrics and Gynaecology 111(7), pp. 688-694. (10.1111/j.1471-0528.2004.00174.x)
• Boralessa, H.et al. 2004. Review of transfusion practice in orthopaedic surgery. Current Orthopaedics 18(2), pp. 126-134. (10.1016/j.cuor.2003.11.001)
• Strang, J. I. G.et al. 2004. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM: An International Journal of Medicine 97(8), pp. 525-535. (10.1093/qjmed/hch086)

2003

• Selden, C.et al. 2003. Characterization of long-term survival of syngeneic hepatocytes in rat peritoneum. Cell Transplantation 12(6), pp. 569-578.

2002

• Maresh, M. J. A.et al. 2002. The VALUE national hysterectomy study: description of the patients and their surgery. BJOG: An International Journal of Obstetrics & Gynaecology 109(3), pp. 302-312. (10.1016/S1470-0328(02)01282-X)